Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients.
BACKGROUND
Epidemiologic data suggest that there is an association between vitamin D deficiency and influenza infection. We conducted a prospective influenza vaccination study to determine the influence of vitamin D status on serological response to influenza vaccine in prostate cancer (CaP) patients.


METHODS
During the 2006-2007 influenza season, CaP patients treated at Roswell Park Cancer Institute were offered vaccination with the trivalent influenza vaccine (Fluzone®, 2006-2007) and sera collected for hemagglutination inhibition (HI) assay titers before and 3 months after vaccination. Response to vaccination was defined as ≥1:40 titer ratio or a fourfold increase in titer at 3 months, against any of the three strains. Serum 25-hydroxyvitamin D (25-D₃) levels were measured using DiaSorin ¹²⁵I radioimmunoassay kits.


RESULTS
Thirty-five patients with CaP participated in the study. Median baseline 25-D₃ level was 44.88 ng/ml (range: 9.16-71.98 ng/ml) Serological response against any of the three strains was noted in 80%. There was a significant effect of baseline 25-D3 level when tested as a continuous variable in relation to serological response (P = 0.0446). All patients in the upper quartile of 25-D3 level responded by mounting a serological response (P = 0.0344). None of the other baseline variables (age, race, chemotherapy status, or white cell count) had an effect on serological response.


CONCLUSIONS
In this study in CaP patients, a replete vitamin D status was associated with more frequent serological response to influenza vaccine.
Chadha
Manpreet K
MK
Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.
Fakih
Marwan
M
Muindi
Josephia
J
Tian
Lili
L
Mashtare
Terry
T
Johnson
Candace S
CS
Trump
Donald
D
D000368:Aged; D006801:Humans; D007252:Influenza Vaccines / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000097:blood / Q000276:immunology*; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000097:blood
D007252:Influenza Vaccines; D014807:Vitamin D; C104450:25-hydroxyvitamin D
J Nutr. 2005 Feb;135(2):317-22
15671234
Br J Cancer. 1999 Apr;80(1-2):219-20
10389999
Cancer. 1979 Nov;44(5):1629-35
498034
N Engl J Med. 1973 Dec 13;289(24):1267-71
4127183
FASEB J. 2005 Jul;19(9):1067-77
15985530
Exp Lung Res. 2007 Dec;33(10):537-42
18075828
BJU Int. 2009 Oct;104(7):909-14
19426195
J Clin Oncol. 2002 Nov 1;20(21):4313-8
12409329
J Laryngol Otol. 2010 May;124(5):465-9
20067648
Virol J. 2008 Feb 25;5:29
18298852
Am J Clin Nutr. 2010 May;91(5):1255-60
20219962
Rev Infect Dis. 1985 Sep-Oct;7(5):613-8
3903940
Epidemiol Infect. 2007 Oct;135(7):1095-6; author reply 1097-8
17352842
Curr Top Microbiol Immunol. 2006;306:153-82
16909921
Int J Colorectal Dis. 2009 Feb;24(2):219-24
18830610
Nat Med. 2006 Apr;12(4):388-90
16598282
Drugs. 2000 Jul;60(1):35-53
10929929
J Immunol. 2004 Sep 1;173(5):2909-12
15322146
Epidemiol Infect. 2006 Dec;134(6):1129-40
16959053
Vaccine. 1999 Apr 9;17(15-16):1883-8
10217585
Epidemiol Infect. 1987 Aug;99(1):5-54
3301379